Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06526299 · ClinicalTrials.gov registry record · Phase 2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

A Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma, sponsored by University of Washington.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 2
Development phase: 51
Enrollment target: 3
Study locations

NCT06526299: Recruiting Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma, sponsored by University of Washington.

NCT06526299 is a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma that is actively recruiting participants, run by University of Washington. The registered enrollment target is 51 participants, below the 176-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06526299, a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status: Phase 2
Development phase: 51 participants
Enrollment target: 3
Study locations

Study Summary

This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate cancer cells and inducing damage to deoxyribonucleic acid (DNA) inside prostate cancer cells. Giving 177Lu-PSMA-617 may improve treatment outcomes for patients with mCRPC.

Primary Outcome

PSA progression is defined as a rise in PSA at \> 12 weeks by more than 25% and more than 2ng/mL above the nadir (lowest PSA point). Time-to-event endpoints will be analyzed graphically and numerically using the Kaplan-Meier method and summarized in terms of median or 1-year survival point estimates with corresponding 95% confidence intervals.

Conditions Studied

Stage IVB Prostate Cancer AJCC v8 Metastatic Castration-resistant Prostate Carcinoma

Interventions

PROCEDURE Biospecimen Collection
PROCEDURE Computed Tomography
PROCEDURE Magnetic Resonance Imaging
PROCEDURE Bone Scan
DRUG Lutetium Lu 177 Vipivotide Tetraxetan

Study Locations (3)

California

University of California San Francisco - San Francisco
Olive View-University of California Los Angeles Medical Center - Sylmar

Washington

Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

Field	Value
Enrollment Target	51 participants
Start Date	2025-04-29
Est. Completion	2027-12-31
Phase	Phase 2

University of Washington

1,048 total trials

What NCT06526299 shows while recruiting

NCT06526299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 176-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (71% lower).

The record links to 2 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06526299 reports a single indexed study location in California, Washington.

Frequently Asked Questions

What is clinical trial NCT06526299 about?

NCT06526299 is a clinical study titled "Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease". This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) comp...

What is the current status of trial NCT06526299?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2025-04-29. Estimated completion is 2027-12-31.

What conditions does trial NCT06526299 study?

This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma.

What interventions are being tested in trial NCT06526299?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Bone Scan (PROCEDURE), Lutetium Lu 177 Vipivotide Tetraxetan (DRUG).

Who is sponsoring clinical trial NCT06526299?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06526299 being conducted?

This trial has 3 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IVB Prostate Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06526299's enrollment target sits among peer trials

51 26th of 45 higher than 20 of 45 other Stage IVB Prostate Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IVB Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06526299, the US trial registry maintained by the National Library of Medicine. NCT06526299 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.